Medical - Pharmaceuticals
Compare Stocks
2 / 10Stock Comparison
LFMD vs TDOC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
LFMD vs TDOC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Pharmaceuticals | Medical - Healthcare Information Services |
| Market Cap | $215M | $1.26B |
| Revenue (TTM) | $219M | $2.51B |
| Net Income (TTM) | $-17M | $-171M |
| Gross Margin | 86.7% | 65.6% |
| Operating Margin | -5.9% | -7.6% |
| Total Debt | $6M | $1.04B |
| Cash & Equiv. | $37M | $781M |
LFMD vs TDOC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| LifeMD, Inc. (LFMD) | 100 | 309.7 | +209.7% |
| Teladoc Health, Inc. (TDOC) | 100 | 4.0 | -96.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LFMD vs TDOC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LFMD is the clearest fit if your priority is long-term compounding.
- 220.7% 10Y total return vs TDOC's -41.1%
- 1.5% yield; the other pay no meaningful dividend
TDOC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.91
- Rev growth -1.5%, EPS growth 80.6%, 3Y rev CAGR 1.7%
- Lower volatility, beta 1.91, Low D/E 75.1%, current ratio 2.69x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -1.5% revenue growth vs LFMD's -8.7% | |
| Value | Better valuation composite | |
| Quality / Margins | -6.8% margin vs LFMD's -7.8% | |
| Stability / Safety | Beta 1.91 vs LFMD's 2.12 | |
| Dividends | 1.5% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | +1.5% vs LFMD's -43.9% | |
| Efficiency (ROA) | -5.9% ROA vs LFMD's -24.3% |
LFMD vs TDOC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
LFMD vs TDOC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
TDOC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TDOC is the larger business by revenue, generating $2.5B annually — 11.5x LFMD's $219M. Profitability is closely matched — net margins range from -6.8% (TDOC) to -7.8% (LFMD). On growth, TDOC holds the edge at -2.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $219M | $2.5B |
| EBITDAEarnings before interest/tax | -$5M | $42M |
| Net IncomeAfter-tax profit | -$17M | -$171M |
| Free Cash FlowCash after capex | $15M | $251M |
| Gross MarginGross profit ÷ Revenue | +86.7% | +65.6% |
| Operating MarginEBIT ÷ Revenue | -5.9% | -7.6% |
| Net MarginNet income ÷ Revenue | -7.8% | -6.8% |
| FCF MarginFCF ÷ Revenue | +6.8% | +10.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -23.6% | -2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -16.0% | +32.1% |
Valuation Metrics
TDOC leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $215M | $1.3B |
| Enterprise ValueMkt cap + debt − cash | $185M | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -19.52x | -6.11x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 15.13x |
| Price / SalesMarket cap ÷ Revenue | 1.11x | 0.50x |
| Price / BookPrice ÷ Book value/share | 8.75x | 0.89x |
| Price / FCFMarket cap ÷ FCF | 33.61x | 4.40x |
Profitability & Efficiency
Evenly matched — LFMD and TDOC each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
TDOC delivers a -12.4% return on equity — every $100 of shareholder capital generates $-12 in annual profit, vs $-162 for LFMD. LFMD carries lower financial leverage with a 0.27x debt-to-equity ratio, signaling a more conservative balance sheet compared to TDOC's 0.75x. On the Piotroski fundamental quality scale (0–9), TDOC scores 6/9 vs LFMD's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -162.4% | -12.4% |
| ROA (TTM)Return on assets | -24.3% | -5.9% |
| ROICReturn on invested capital | — | -11.5% |
| ROCEReturn on capital employed | -37.4% | -10.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.27x | 0.75x |
| Net DebtTotal debt minus cash | -$30M | $259M |
| Cash & Equiv.Liquid assets | $37M | $781M |
| Total DebtShort + long-term debt | $6M | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | -6.48x | -8.76x |
Total Returns (Dividends Reinvested)
LFMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LFMD five years ago would be worth $5,423 today (with dividends reinvested), compared to $461 for TDOC. Over the past 12 months, TDOC leads with a +1.5% total return vs LFMD's -43.9%. The 3-year compound annual growth rate (CAGR) favors LFMD at 40.8% vs TDOC's -35.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +28.7% | -1.3% |
| 1-Year ReturnPast 12 months | -43.9% | +1.5% |
| 3-Year ReturnCumulative with dividends | +178.9% | -73.3% |
| 5-Year ReturnCumulative with dividends | -45.8% | -95.4% |
| 10-Year ReturnCumulative with dividends | +220.7% | -41.1% |
| CAGR (3Y)Annualised 3-year return | +40.8% | -35.6% |
Risk & Volatility
TDOC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TDOC is the less volatile stock with a 1.91 beta — it tends to amplify market swings less than LFMD's 2.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TDOC currently trades 71.2% from its 52-week high vs LFMD's 28.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.12x | 1.91x |
| 52-Week HighHighest price in past year | $15.84 | $9.77 |
| 52-Week LowLowest price in past year | $2.56 | $4.40 |
| % of 52W HighCurrent price vs 52-week peak | +28.3% | +71.2% |
| RSI (14)Momentum oscillator 0–100 | 70.8 | 74.1 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 5.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates LFMD as "Buy" and TDOC as "Hold". Consensus price targets imply 89.3% upside for LFMD (target: $9) vs 8.9% for TDOC (target: $8). LFMD is the only dividend payer here at 1.53% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $8.50 | $7.58 |
| # AnalystsCovering analysts | 10 | 42 |
| Dividend YieldAnnual dividend ÷ price | +1.5% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $0.07 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
TDOC leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). LFMD leads in 1 (Total Returns). 1 tied.
LFMD vs TDOC: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is LFMD or TDOC a better buy right now?
For growth investors, Teladoc Health, Inc.
(TDOC) is the stronger pick with -1. 5% revenue growth year-over-year, versus -8. 7% for LifeMD, Inc. (LFMD). Analysts rate LifeMD, Inc. (LFMD) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LFMD or TDOC?
Over the past 5 years, LifeMD, Inc.
(LFMD) delivered a total return of -45. 8%, compared to -95. 4% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: LFMD returned +220. 7% versus TDOC's -41. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LFMD or TDOC?
By beta (market sensitivity over 5 years), Teladoc Health, Inc.
(TDOC) is the lower-risk stock at 1. 91β versus LifeMD, Inc. 's 2. 12β — meaning LFMD is approximately 11% more volatile than TDOC relative to the S&P 500. On balance sheet safety, LifeMD, Inc. (LFMD) carries a lower debt/equity ratio of 27% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — LFMD or TDOC?
By revenue growth (latest reported year), Teladoc Health, Inc.
(TDOC) is pulling ahead at -1. 5% versus -8. 7% for LifeMD, Inc. (LFMD). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to 56. 6% for LifeMD, Inc.. Over a 3-year CAGR, LFMD leads at 17. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LFMD or TDOC?
LifeMD, Inc.
(LFMD) is the more profitable company, earning -3. 7% net margin versus -7. 9% for Teladoc Health, Inc. — meaning it keeps -3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LFMD leads at -4. 0% versus -10. 4% for TDOC. At the gross margin level — before operating expenses — LFMD leads at 79. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LFMD or TDOC?
In this comparison, LFMD (1.
5% yield) pays a dividend. TDOC does not pay a meaningful dividend and should not be held primarily for income.
07Is LFMD or TDOC better for a retirement portfolio?
For long-horizon retirement investors, LifeMD, Inc.
(LFMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1. 5% yield, +220. 7% 10Y return). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LFMD: +220. 7%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LFMD and TDOC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
LFMD pays a dividend while TDOC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.